TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2184356

Group type: EXPERIMENTAL
Intervention: Recombinant interferon alfa-2b (n = 50)
Number of subjects: 101

Group type: COMPARATOR
Intervention: No treatment (control group, n = 51)
Number of subjects: 101
Study: 7292376

Group type: EXPERIMENTAL
Intervention: Prednisolone 20 mg twice daily for three weeks
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo for the first week
Number of subjects: 19
Study: 31197389

Group type: COMPARATOR
Intervention: Arthroscopic Broström repair technique (ABR)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Arthroscopic lateral ligaments augmentation using suture-tape internal bracing (AST)
Number of subjects: 61
Study: 30860492

Group type: EXPERIMENTAL
Intervention: Get Healthy, Stay Healthy (GHSH) intervention, n=114
Number of subjects: 228

Group type: COMPARATOR
Intervention: Standard care (no additional contact), n=114
Number of subjects: 228
Study: 28192551

Group type: EXPERIMENTAL
Intervention: Computerized clinical decision support system (T2D module)
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Control group (no T2D module)
Number of subjects: 1369
Study: 27136907

Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate 100 mg eq. (156 mg of PP) administered via deltoid injections
Number of subjects: 49

Group type: COMPARATOR
Intervention: Paliperidone palmitate 100 mg eq. (156 mg of PP) administered via gluteal injections
Number of subjects: 49
Study: 23262383

Group type: EXPERIMENTAL
Intervention: Vapocoolant spray
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (no pretreatment)
Number of subjects: 99
Study: 21991738

Group type: EXPERIMENTAL
Intervention: Continuous suprascapular nerve block under ultrasound guidance plus rehabilitation program
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intra-articular corticosteroid injection plus rehabilitation program
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rehabilitation program only
Number of subjects: 50
Study: 19210144

Group type: EXPERIMENTAL
Intervention: Mean common CIMT protocols measuring both near and far wall at >= 2 angles
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Mean maximum protocol measuring three segments at >= 2 angles
Number of subjects: 675

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 675

Group type: EXPERIMENTAL
Intervention: Duplicate scans
Number of subjects: 675
Study: 16019102

Group type: EXPERIMENTAL
Intervention: Nurse case management (NCM)
Number of subjects: 332

Group type: COMPARATOR
Intervention: Usual care by primary care provider
Number of subjects: 332
Study: 12615585

Group type: COMPARATOR
Intervention: Intravenous fentanyl (1.5 micro g/kg)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Nebulized fentanyl (1.5 micro g/kg)
Number of subjects: 50
Study: 10848718

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (400 mg daily for 8 days)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study: 9313642

Group type: EXPERIMENTAL
Intervention: rTMS over supplementary motor area
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: rTMS over primary motor cortex
Number of subjects: 15

Group type: COMPARATOR
Intervention: rTMS over other positions (e.g. F3, F4, FCz, P3, P4)
Number of subjects: 15
Study: 8371727

Group type: EXPERIMENTAL
Intervention: Hypothermic circulatory arrest
Number of subjects: 171

Group type: COMPARATOR
Intervention: Low-flow cardiopulmonary bypass
Number of subjects: 171
Study: 2878130

Group type: EXPERIMENTAL
Intervention: Consolidation with six courses of DAT (daunorubicin, cytarabine, and 6-thioguanine)
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Late intensification with cyclophosphamide, vincristine, cytarabine, and prednisolone (COAP)
Number of subjects: 1127

Group type: COMPARATOR
Intervention: CNS prophylaxis with intrathecal cytarabine and methotrexate
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Histocompatible allogeneic bone-marrow transplants in first remission
Number of subjects: 1127

Group type: EXPERIMENTAL
Intervention: Overall treatment during the trial
Number of subjects: 1127
Study: 31350814

Group type: EXPERIMENTAL
Intervention: Purgenesis™ Day Cream, Purgenesis™ Eye Cream, and Purgenesis™ Night Cream
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Prevage® Eye Lotion, Prevage® Day Cream, and Prevage® Night Cream
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: La Mer® Eye Balm, Crème de La Mer®, and La Mer® Night Cream
Number of subjects: 72

Group type: COMPARATOR
Intervention: Group B (Prevage®)
Number of subjects: 72
Study: 29494818

Group type: EXPERIMENTAL
Intervention: Extended nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy (paclitaxel 135 mg/m2 day 1 and cisplatin 20 mg/m2 days 1‐3, every 4 weeks) plus erlotinib (150 mg per day during chemoradiotherapy)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Extended nodal irradiation (ENI) with two cycles of concurrent TP chemotherapy
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy plus erlotinib
Number of subjects: 352

Group type: COMPARATOR
Intervention: Conventional field irradiation (CFI) with two cycles of concurrent TP chemotherapy
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Extended nodal irradiation (ENI)
Number of subjects: 352

Group type: EXPERIMENTAL
Intervention: Erlotinib
Number of subjects: 352
Study: 26810269

Group type: EXPERIMENTAL
Intervention: Glibenclamide
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 50
Study: 24374549

Group type: EXPERIMENTAL
Intervention: Semuloparin 20 mg commenced postoperatively
Number of subjects: 4413

Group type: COMPARATOR
Intervention: Enoxaparin 40 mg commenced preoperatively
Number of subjects: 4413
Study: 23340895

Group type: EXPERIMENTAL
Intervention: IMI 20 min
Number of subjects: 100

Group type: COMPARATOR
Intervention: No IMI
Number of subjects: 100
Study: 20602568

Group type: EXPERIMENTAL
Intervention: PEG + Asc (2 l PEG + ascorbic acid)
Number of subjects: 350

Group type: COMPARATOR
Intervention: PEG (4 l PEG solution)
Number of subjects: 350
Study: 17631877

Group type: EXPERIMENTAL
Intervention: Typicality effect in sentence production
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ad hoc categories
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carefully matched sentences with two category members
Number of subjects: 0
Study: 16633762

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (SEV, n = 31)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intravenous propofol, fentanyl, and vecuronium anesthesia (TIVA, n = 30)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Sevoflurane anesthesia (SEV)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Intravenous propofol, fentanyl, and vecuronium anesthesia (TIVA)
Number of subjects: 61
Study: 14749744

Group type: EXPERIMENTAL
Intervention: Sheep's dairy fat
Number of subjects: 41

Group type: COMPARATOR
Intervention: Cows' dairy fat
Number of subjects: 41
Study: 11729013

Group type: EXPERIMENTAL
Intervention: 20 mg/day of paroxetine
Number of subjects: 551

Group type: EXPERIMENTAL
Intervention: 40 mg/day of paroxetine
Number of subjects: 551

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 551
Study: 9845027

Group type: EXPERIMENTAL
Intervention: Cochlear implantation before schooling
Number of subjects: 121

Group type: COMPARATOR
Intervention: Cochlear implantation during educational placement
Number of subjects: 121
Study: 7837157

Group type: EXPERIMENTAL
Intervention: Patients with OA of the knee
Number of subjects: 48

Group type: COMPARATOR
Intervention: Subjects without OA of the knee
Number of subjects: 48
Study: 3069498

Group type: EXPERIMENTAL
Intervention: Intra-arterial instillation of 0.5 mg reserpine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline alone
Number of subjects: 50
Study: 29316715

Group type: EXPERIMENTAL
Intervention: Medium-Intensity Continuous Training (MIT, n = 21, 60% of VO2max)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIT, n = 20, 100-200% of VO2max)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (n = 40)
Number of subjects: 41
Study: 26777329

Group type: EXPERIMENTAL
Intervention: Sirolimus-Eluting Stenting (SES)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Plain Balloon Angioplasty (PTA)
Number of subjects: 200
Study: 25911281

Group type: EXPERIMENTAL
Intervention: OCD checkers
Number of subjects: 0

Group type: COMPARATOR
Intervention: OCD washers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-patients
Number of subjects: 0
Study: 23632034

Group type: EXPERIMENTAL
Intervention: Low-fat labeling with caloric information
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: Low-fat labeling
Number of subjects: 175

Group type: COMPARATOR
Intervention: Regular-labeled candy
Number of subjects: 175
Study: 21070720

Group type: EXPERIMENTAL
Intervention: PEPAF (program promoting physical activity)
Number of subjects: 3698

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 3698
Study: 19008680

Group type: EXPERIMENTAL
Intervention: Cognitive-linguistic treatment
Number of subjects: 58
Study: 16785475

Group type: EXPERIMENTAL
Intervention: Abatacept (10 mg/kg body weight, once-monthly infusion)
Number of subjects: 652
Study: 12697204

Group type: EXPERIMENTAL
Intervention: Volitional intervention
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Combined motivational plus volitional intervention
Number of subjects: 271

Group type: COMPARATOR
Intervention: Motivational intervention
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 271
Study: 10955205

Group type: EXPERIMENTAL
Intervention: 7 treatment groups with different kinds of tutor modeling (whole word, letter-phoneme, combined whole word and letter-phoneme)
Number of subjects: 128

Group type: EXPERIMENTAL
Intervention: Whole word, letter-phoneme, and combined whole word and letter-phoneme modeling
Number of subjects: 128

Group type: COMPARATOR
Intervention: Contact control group that received phonological and orthographic awareness training without explicit instruction on orthographic-phonological connections
Number of subjects: 128
Study: 9361342

Group type: EXPERIMENTAL
Intervention: Antithrombin III (AT III) supplementation for 14 days
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 8251355

Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg at night
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 3513564

Group type: EXPERIMENTAL
Intervention: Inhaled metaproterenol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Oral metaproterenol
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination of inhaled and oral metaproterenol
Number of subjects: 20
Study: 31655485

Group type: EXPERIMENTAL
Intervention: losartan (50 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study: 29727794

Group type: EXPERIMENTAL
Intervention: Clinical demonstration video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Practitioner role play video
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical demonstration video (Phase 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical demonstration video (Phase 3)
Number of subjects: 0
Study: 27508274

Group type: EXPERIMENTAL
Intervention: COH + TS + chlorhexidine + probiotics (Group D)
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: COH + TS + chlorhexidine (Group C)
Number of subjects: 208

Group type: COMPARATOR
Intervention: COH (Group A)
Number of subjects: 208

Group type: COMPARATOR
Intervention: COH + tongue scraping (Group B)
Number of subjects: 208
Study: 24691452

Group type: EXPERIMENTAL
Intervention: PVI with renal denervation (RD)
Number of subjects: 86

Group type: COMPARATOR
Intervention: PVI only
Number of subjects: 86
Study: 22455564

Group type: EXPERIMENTAL
Intervention: High-intensity aerobic interval training (AIT)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Strength training (ST)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 20357664

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 132

Group type: COMPARATOR
Intervention: SNRIs (duloxetine and venlafaxine)
Number of subjects: 132
Study: 19014549

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 800 microg QD PM
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Mometasone furoate 400 microg BID
Number of subjects: 911

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 911

Group type: EXPERIMENTAL
Intervention: Pooled MF‐DPI groups
Number of subjects: 911
Study: 15824294

Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance training for 6 months
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care physical activity and diet advice (Control)
Number of subjects: 104
Study: 12854895

Group type: EXPERIMENTAL
Intervention: CHOP-HC (high dose cyclophosphamide consolidation)
Number of subjects: 25

Group type: COMPARATOR
Intervention: CHOP (control)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: CHOP-HC
Number of subjects: 25

Group type: COMPARATOR
Intervention: CHOP
Number of subjects: 25
Study: 10536557

Group type: EXPERIMENTAL
Intervention: rocuronium 0.9 mg kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: succinylcholine 1.5 mg kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: both groups
Number of subjects: 30
Study: 8671562

Group type: EXPERIMENTAL
Intervention: Controlled intervention to reduce unjustified hospital stay days (HSD)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Control ward (N=248)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Both wards (study and control)
Number of subjects: 155
Study: 2016626

Group type: COMPARATOR
Intervention: Interferon alfa-n1 alone
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Interferon alfa-n1 with vinblastine
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Subset of patients with pulmonary metastases
Number of subjects: 165
Study: 6293296

Group type: EXPERIMENTAL
Intervention: Lentils boiled for 20 min
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Blended lentils to a paste
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lentils boiled for an additional 40 minutes
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Dried boiled blended lentils for 12 h at 250 degrees F
Number of subjects: 8

Group type: COMPARATOR
Intervention: White bread (control)
Number of subjects: 8
Study: 31323685

Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT)
Number of subjects: 84
Study: 30999196

Group type: EXPERIMENTAL
Intervention: TXA single dose
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TXA two doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 0
Study: 27685009

Group type: EXPERIMENTAL
Intervention: Dry Needling (DN)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo laser plus water pressure massage
Number of subjects: 30

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 30
Study: 26242249

Group type: EXPERIMENTAL
Intervention: EQ-5D-5L questionnaire
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Uruguayan EQ-5D-5L value set
Number of subjects: 794

Group type: COMPARATOR
Intervention: Comparison with Argentinian EQ-5D-5L crosswalk value set
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Age and gender analysis
Number of subjects: 794
Study: 24346155

Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin 12 hours and 40 mg atorvastatin 2 hours before PCI
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 40 mg atorvastatin preoperatively for 7 days
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no atorvastatin)
Number of subjects: 45
Study: 21685819

Group type: EXPERIMENTAL
Intervention: Ingestion of 25 mL of plain water before and every 5 min (DR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Mouth rinse with 25 mL of plain water before and every 5 min (MR)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (CON), where no fluids were provided
Number of subjects: 10
Study: 19614721

Group type: EXPERIMENTAL
Intervention: Microsurgical access flap with EMD
Number of subjects: 70

Group type: COMPARATOR
Intervention: Microsurgical access flap alone (Control)
Number of subjects: 70
Study: 17241841

Group type: EXPERIMENTAL
Intervention: Contraceptive counseling with optional advance EC prescription
Number of subjects: 737

Group type: COMPARATOR
Intervention: No contraceptive or EC counseling
Number of subjects: 737
Study: 15241771

Group type: EXPERIMENTAL
Intervention: 30 minutes at 75% Vo(2)max
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 10 minutes at 75% Vo(2)max
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 30 minutes at 50% Vo(2)max
Number of subjects: 12
Study: 12625668

Group type: EXPERIMENTAL
Intervention: Methyldopa 750‐4000 mg/day (n=34)
Number of subjects: 70

Group type: COMPARATOR
Intervention: No treatment (n=36)
Number of subjects: 70
Study: 10986365

Group type: EXPERIMENTAL
Intervention: Demonstrated function
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow response time
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Function consideration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lexical and non-lexical conditions
Number of subjects: 0
Study: 8829020

Group type: EXPERIMENTAL
Intervention: Nisoldipine 5 mg twice daily
Number of subjects: 91

Group type: COMPARATOR
Intervention: Isosorbide dinitrate 40 mg sustained-release
Number of subjects: 91
Study: 1452083

Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Oesophageal transection and gastric devascularisation
Number of subjects: 92
Study: 6710092

Group type: EXPERIMENTAL
Intervention: Self-training with follow-up control of results
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 20
Study: 30982761

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg daily for 5 days preoperatively, the morning of surgery, and the first postoperative day
Number of subjects: 131

Group type: COMPARATOR
Intervention: Placebo daily for 5 days preoperatively, the morning of surgery, and the first postoperative day
Number of subjects: 131
Study: 30024924

Group type: EXPERIMENTAL
Intervention: Bedaquiline
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 27461399

Group type: EXPERIMENTAL
Intervention: Intramuscular olanzapine
Number of subjects: 80

Group type: COMPARATOR
Intervention: Intramuscular aripiprazole
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 80
Study: 23904470

Group type: EXPERIMENTAL
Intervention: Early MRI measures (baseline and changes at weeks 12 and 24)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Regression models incorporating baseline and 12-week and 24-week changes in MRI measures
Number of subjects: 256
Study: 22685559

Group type: EXPERIMENTAL
Intervention: PINCER intervention
Number of subjects: 0
Study: 20055763

Group type: EXPERIMENTAL
Intervention: Ropivacaine 2 mg/ml
Number of subjects: 16

Group type: COMPARATOR
Intervention: Saline
Number of subjects: 16
Study: 18726957

Group type: COMPARATOR
Intervention: 5 ml lidocaine (group L)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: 5 ml lidocaine + 0.5 mg dinitrate isosorbide (group LN)
Number of subjects: 84
Study: 15735447

Group type: EXPERIMENTAL
Intervention: Nevirapine (NVP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Efavirenz (EFV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nevirapine + Efavirenz (NVP + EFV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline pVL >100,000 copies/mL
Number of subjects: 0

Group type: COMPARATOR
Intervention: High VDc
Number of subjects: 0
Study: 12562741

Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy (DBT) for 12 months
Number of subjects: 58

Group type: COMPARATOR
Intervention: Usual treatment
Number of subjects: 58
Study: 10567276

Group type: EXPERIMENTAL
Intervention: Pulmonary autograft
Number of subjects: 25

Group type: COMPARATOR
Intervention: Aortic homograft
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Both groups (homografts and autografts)
Number of subjects: 25
Study: 8764554

Group type: EXPERIMENTAL
Intervention: Tonsillectomy
Number of subjects: 25
Study: 1925058

Group type: EXPERIMENTAL
Intervention: Different distance group (20 degrees left hand, 60 degrees right hand)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison group (20 degrees in each limb)
Number of subjects: 60
Study: 29490675

Group type: EXPERIMENTAL
Intervention: Simplified cardiovascular management program delivered by village doctors
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Simplified cardiovascular management program
Number of subjects: 28
Study: 27471314

Group type: EXPERIMENTAL
Intervention: Clonidine 1 µg·kg(‐1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Clonidine 1 µg·kg(‐1) and ketamine 1 mg·kg(‐1)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 75
Study: 24864045

Group type: EXPERIMENTAL
Intervention: Higher heart rate in patients in sinus rhythm (categorical and continuous analysis)
Number of subjects: 3967

Group type: COMPARATOR
Intervention: Beta-blocker treatment
Number of subjects: 3967

Group type: COMPARATOR
Intervention: Heart rate in patients in atrial fibrillation
Number of subjects: 3967
Study: 22266895

Group type: EXPERIMENTAL
Intervention: 500 mg oral clarithromycin twice daily for 5 months
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 20452258

Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany (SE)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: gutta‐percha/AH‐Plus
Number of subjects: 100
Study: 18039954

Group type: EXPERIMENTAL
Intervention: Valganciclovir 450 mg orally twice daily
Number of subjects: 40

Group type: COMPARATOR
Intervention: Valaciclovir 500 mg orally daily
Number of subjects: 40
Study: 16046717

Group type: EXPERIMENTAL
Intervention: Early childhood development (ECD) intervention
Number of subjects: 313

Group type: COMPARATOR
Intervention: Nutrition intervention
Number of subjects: 313
Study: 12126385

Group type: EXPERIMENTAL
Intervention: 10 mg of hydrocodone/1000 mg of acetaminophen
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 9891150

Group type: EXPERIMENTAL
Intervention: Independent study of resident-prepared chest radiology teaching cases
Number of subjects: 65

Group type: COMPARATOR
Intervention: Control group (no independent study)
Number of subjects: 65